Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 13/20 | 1.00 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | AHCY | P23526 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22501965 | 1.00 | PRMT5 (1.00) | PRMT5WDR77ADORA1AHCYADORA3 | |
| SCHEMBL22501964 | 1.00 | PRMT5 (1.00) | PRMT5WDR77ADORA1AHCYADORA3 | |
| SCHEMBL29706082 | 0.93 | PRMT5 (1.00) | PRMT5WDR77ADORA1AHCY | |
| SCHEMBL22501904 | 0.93 | PRMT5 (1.00) | PRMT5WDR77ADORA1AHCY | |
| SCHEMBL22501903 | 0.93 | PRMT5 (1.00) | PRMT5WDR77ADORA1AHCY | |
| SCHEMBL23294566 | 0.91 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3 | |
| SCHEMBL22509067 | 0.91 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3 | |
| SCHEMBL29706001 | 0.91 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3 | |
| SCHEMBL22509045 | 0.89 | PRMT5 (0.82) | PRMT5WDR77ADORA1AHCYADORA3 | |
| SCHEMBL23294157 | 0.89 | PRMT5 (0.82) | PRMT5WDR77ADORA1AHCYADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250346618-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250339437-A1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025217420-A1 | PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4069697-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025101598-A1 | BI-CYCLIC PYRIMIDINE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-119343340-A | Methods of preparing modified BTK inhibitors | 普林斯匹亚生物制药公司 | 2025-01-21 | — | — | CN | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-113307811-B | Tetrahydropyranyl amino-pyrrolopyrimidinones and methods of use thereof | 艾科尔公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-115989209-A | Monosubstituted cyclopentadiene and metal cyclopentadienyl complex and its synthesis method | 乔治洛德方法研究和开发液化空气有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3882250-B1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE FOR USE IN TREATING BTK-MEDIATED DISORDERS | ARQULE INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4069697-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | PRMT5 1596/4885WDR77 3430/4885ADORA1 4807/4885 |
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRH, CRHR2 | PRMT5 3051/4885WDR77 1435/4885ADORA1 264/4885 |
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | BTK, TEC, SYK | PRMT5 1078/4885WDR77 480/4885ADORA1 4412/4885 |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 52/4885ADORA1 4710/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | PRMT5 1596/4885WDR77 3430/4885ADORA1 4807/4885 |
| US-20250346618-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OPRD1 | PRMT5 1323/4885WDR77 4259/4885ADORA1 2118/4885 |
| US-20250339437-A1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF | BTK, SYK, LCK | PRMT5 1436/4885WDR77 2181/4885ADORA1 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.